Crystal structure and interaction studies of human DHTKD1 provide insight into a mitochondrial megacomplex in lysine catabolism
Authors:
- Gustavo A. BezerraGBGustavo A. Bezerra
- William R. FosterWFWilliam R. Foster
- Henry J. BaileyHBHenry J. Bailey
- Kevin G. HicksKHKevin G. Hicks
- Sven W. SauerSSSven W. Sauer
- Bianca DimitrovBDBianca Dimitrov
- Thomas J. McCorvieTMThomas J. McCorvie
- Jürgen G. OkunJOJürgen G. Okun
- Jared RutterJRJared Rutter
- Stefan KölkerSKStefan Kölker
- Wyatt W. YueWYWyatt W. Yue
Open Access
- 10 June 2020
- journal article
- research article
- Published by International Union of Crystallography (IUCr) in IUCrJ
- Vol. 7 (4) , 693-706
Abstract
DHTKD1 is a lesser-studied E1 enzyme among the family of 2-oxoacid dehydrogenases. In complex with E2 (dihydrolipoamide succinyltransferase, DLST) and E3 (dihydrolipoamide dehydrogenase, DLD) components, DHTKD1 is involved in lysine and tryptophan catabolism by catalysing the oxidative decarboxylation of 2-oxoadipate (2OA) in mitochondria. Here, the 1.9 Å resolution crystal structure of human DHTKD1 is solved in complex with the thiamine diphosphate co-factor. The structure reveals how the DHTKD1 active site is modelled upon the well characterized homologue 2-oxoglutarate (2OG) dehydrogenase but engineered specifically to accommodate its preference for the longer substrate of 2OA over 2OG. A 4.7 Å resolution reconstruction of the human DLST catalytic core is also generated by single-particle electron microscopy, revealing a 24-mer cubic scaffold for assembling DHTKD1 and DLD protomers into a megacomplex. It is further demonstrated that missense DHTKD1 variants causing the inborn error of 2-aminoadipic and 2-oxoadipic aciduria impact on the complex formation, either directly by disrupting the interaction with DLST, or indirectly through destabilizing the DHTKD1 protein. This study provides the starting framework for developing DHTKD1 modulators to probe the intricate mitochondrial energy metabolism.Keywords
All Related Versions
Funding Information
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Eshelman Innovation
- Genome Canada
- Innovative Medicines Initiative (115766)
- Janssen Pharmaceutica
- Merck
- Novartis Pharma
- Ontario Ministry of Economic Development and Innovation
- Pfizer
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Takeda Pharmaceuticals U.S.A.
- Wellcome Trust (092809/Z/10/Z)
This publication has 68 references indexed in Scilit:
- DHTKD1 Mutations Cause 2-Aminoadipic and 2-Oxoadipic AciduriaThe American Journal of Human Genetics, 2012
- A Nonsense Mutation in DHTKD1 Causes Charcot-Marie-Tooth Disease Type 2 in a Large Chinese PedigreeThe American Journal of Human Genetics, 2012
- Prevention of overfitting in cryo-EM structure determinationNature Methods, 2012
- Interaction of E1 and E3 components with the core proteins of the human pyruvate dehydrogenase complexJournal of Molecular Catalysis B: Enzymatic, 2009
- CHAINSAW: a program for mutating pdb files used as templates in molecular replacementJournal of Applied Crystallography, 2008
- Inference of Macromolecular Assemblies from Crystalline StateJournal of Molecular Biology, 2007
- A synchronized substrate‐gating mechanism revealed by cubic‐core structure of the bovine branched‐chain α‐ketoacid dehydrogenase complexThe EMBO Journal, 2006
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- CRYSOL– a Program to Evaluate X-ray Solution Scattering of Biological Macromolecules from Atomic CoordinatesJournal of Applied Crystallography, 1995
- Determination of the regularization parameter in indirect-transform methods using perceptual criteriaJournal of Applied Crystallography, 1992